Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease

Neurology

Volumn 62, Issue 11, 2004, Pages 1977-1983

  Tiraboschi, P ^a,b   Hansen, L A ^b   Masliah, E ^b   Alford, M ^b   Thal, L J ^b,c   Corey Bloom, J ^b,c,d  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BIOCHEMICAL MARKER; CHOLINE ACETYLTRANSFERASE;

AGED; ALLELE; ALZHEIMER DISEASE; APOE GENE; ARTICLE; BRAIN INJURY; CHOLINERGIC SYSTEM; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; GENE; GENOTYPE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEURITIC PLAQUE; NEUROCHEMISTRY; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; ONSET AGE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SENILE PLAQUE;

EID: 2942536666     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000128091.92139.0F     Document Type: Article

References (40)

1. Bennett DA, Wilson RS, Schneider JA, et al. Apolipoprotein E ε4 allele, AD pathology, and the clinical expression of Alzheimer's disease. Neurology 2003;60:246-252.
2. Sparks DL, Scheff SW, Liu H, et al. Increased density of senile plaques (SP), but not neurofibrillary tangles (NFT), in non-demented individuals with the apolipoprotein E4 allele: comparison to confirmed Alzheimer's disease patients. J Neurol Sci 1996;138:97-104.
3. Ghebremedin E, Schultz C, Thal DR, et al. Gender and age modify the association between APOE and AD-related neuropathology. Neurology 2001;56:1696-1701.
4. Nagy ZA, Esiri MM, Jobst KA, et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 1995;69:757-761.
5. Olichney JM, Hansen LA, Galasko D, et al. The apolipoprotein E ε4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Neurology 1996;47:190-196.
6. Ohm TG, Kirca M, Bohl J, et al. Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience 1995;66:583-587.
7. Landen M, Thorsell A, Wallin A, Blennow K. The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1996;61:352-356.
8. Heinonen O, Lethovirta M, Soininen H, et al. Alzheimer pathology of patients carrying apolipoprotein E ε4 allele. Neurobiol Aging 1995;16:505-513.
9. Morris CM, Benjamin R, Leake A, et al. Effect of apolipoprotein E genotype on Alzheimer's disease neuropathology in a cohort of elderly Norwegians. Neurosci Lett 1995;201:45-48.
10. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer's disease. Proc Natl Acad Sci USA 1993;90:9649-9653.
11. Strittmatter WJ, Saunders AM, Schmechel DE, et al. Apolipoprotein E: high avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad Sci USA 1993;90:1997-1981.
12. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993;11:575-580.
13. Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 1995;333:1242-1247.
14. Namba Y, Tomonaga M, Kawasaki H, Ohtomo E, Ikeda E. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and Kuru plaque amyloid in Creutzfeldt-Jacob disease. Brain Res 1991;541:163-166.
15. Burns MP, Noble WJ, Olm V, et al. Co-localization of cholesterol, apolipoprotein E and fibrillar Abeta in amyloid plaques. Brain Res Mol Brain Res 2003;110:119-125.
16. Dickson TC, Saunders HL, Vickers JC. Relationship between apolipoprotein E and the amyloid deposits and dystrophic neurites of Alzheimer's disease. Neuropathol Appl Neurobiol 1997;23:483-491.
17. Metzger RE, LaDu MJ, Pan JB, Getz GS, Frail DE, Falduto MT. Neurons of the human frontal cortex display apolipoprotein E immunoreactivity: implications for Alzheimer's disease. J Neuropathol Exp Neurol 1996;55:372-380.
18. Strittmatter WJ, Weisgraber KH, Goedert M, et al. Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer's disease brain are related to apolipoprotein E genotype. Exp Neurol 1994;125:163-171.
19. Thaker U, McDonagh AM, Iwatsubo T, Lendon CL, Pickering-Brown SM, Mann DMA. Tau load is associated with apolipoprotein E genotype and the amount of amyloid b protein, Ab40, in sporadic and familial Alzheimer's disease. Neuropathol Appl Neurobiol 2003;29:35-44.
20. Ohm TG, Scharnagl H, Marz W, Bohl H. Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions. Acta Neuropathol 1999;98:273-280.
21. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E e4 in Alzheimer's disease. Ann Neurol 1996;39:62-70.
22. Berg L, McKeel DW, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease. Arch Neurol 1998;55:326-335.
23. Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein ε4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc Natl Acad Sci USA 1995;92:12260-12264.
24. Allen SJ, MacGowan SH, Tyler S, et al. Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype. Neurosci Lett 1997;239:33-36.
25. Soininen H, Kosunen O, Helisalmi S, et al. A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein ε4 allele. Neurosci Lett 1995;187:79-82.
26. Morris CM, Massey HM, Benjamin R, Leake A, et al. Molecular biology of APOE alleles in Alzheimer's and non Alzheimer's dementias. J Neural Transm 1996;47(suppl):205-218.
27. Svensson AL, Warpman U, Hellstrom-Lindahl E, et al. Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotypes. Neurosci Lett 1997;232:37-40.
28. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985;42:1097-1105.
29. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
30. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington, DC: American Psychiatric Press, 1987.
31. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group. Neurology 1984;34:939-944.
32. Terry RD, Peck A, DeTeresa R, Schecter R, Horoupian DS. Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol 1981;10:184-192.
33. Samuel W, Galasko D, Masliah E, Hansen LA. Neocortical Lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease. J Neuropathol Exp Neurol 1996;55:44-52.
34. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259.
35. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology 1996;47:1113-1124.
36. Wenham PR, Price WM, Blundell G. Apolipoprotein E genotyping by one-stage PCR. Lancet 1991;337:1158-1159.
37. Fonnum F. A rapid radiochemical method of determination of choline acetyltransferase. J Neurochem 1975;24:407-409.
38. Hansen LA, DeTeresa R, Davies P, Terry RD. Neocortical morphometry, lesion counts, and choline acetyltransferase levels in the age spectrum of Alzheimer's disease. Neurology 1988;38:48-54.
39. Corder EH, Saunders AM, Risch NJ, et al. Apolipoprotein E type 2 allele decreases the risk of late-onset Alzheimer disease. Nat Genet 1994;7:180-184.
40. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.